Stryker saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 73 to 81.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Stryker is working on a flat base with a 406.19 entry. See if the stock can clear the breakout price in heavy volume.
The company posted 16% EPS growth in the latest quarterly report. Sales increased 11%.
Stryker earns the No. 7 rank among its peers in the Medical-Products industry group. Boston Scientific, Axogen and Penumbra are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
